Taytulla Patent Expiration

Taytulla is a drug owned by Allergan Pharmaceuticals International Ltd. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 29, 2020. Details of Taytulla's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6652880 Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
Mar, 2020

(4 years ago)

Expired
US5552394 Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
Jul, 2014

(10 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Taytulla's patents.

Given below is the list of recent legal activities going on the following patents of Taytulla.

Activity Date Patent Number
Patent litigations
File Marked Found 05 Apr, 2017 US6652880
Recordation of Patent Grant Mailed 25 Nov, 2003 US6652880
Patent Issue Date Used in PTA Calculation 25 Nov, 2003 US6652880
Issue Notification Mailed 06 Nov, 2003 US6652880
Receipt into Pubs 16 Oct, 2003 US6652880
Application Is Considered Ready for Issue 13 Oct, 2003 US6652880
Receipt into Pubs 01 Oct, 2003 US6652880
Issue Fee Payment Received 25 Aug, 2003 US6652880
Issue Fee Payment Verified 25 Aug, 2003 US6652880
Receipt into Pubs 18 Aug, 2003 US6652880

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Taytulla is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Taytulla's family patents as well as insights into ongoing legal events on those patents.

Taytulla's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Taytulla's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 29, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Taytulla Generics:

Ethinyl Estradiol; Norethindrone Acetate is the generic name for the brand Taytulla. 15 different companies have already filed for the generic of Taytulla, with Xiromed having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Taytulla's generic

Alternative Brands for Taytulla

Taytulla which is used for contraception., has several other brand drugs in the same treatment category and using the same active ingredient (Ethinyl Estradiol; Norethindrone Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Apil
Femcon Fe Used for contraception.
Lo Minastrin Fe

(uses Ethinyl Estradiol; Norethindrone Acetate)

Used for preventing pregnancy.
Minastrin 24 Fe

(uses Ethinyl Estradiol; Norethindrone Acetate)

Used for contraception.
Bayer Hlthcare
Yaz Used for contraception, prevention of pregnancy, and treating premenstrual dysphoric disorder in premenopausal females.
Beyaz Used for contraception, prevention of pregnancy, and treating mood changes and anxiety in women with PMDD who choose oral contraceptives.
Yasmin Used for contraception.
Natazia Used for preventing pregnancy and treating heavy menstrual bleeding in women who use oral contraceptives.
Safyral Used for preventing pregnancy and raising folate levels to reduce the risk of neural tube defects in pregnancy.
Evofem Inc
Phexxi used for contraception.
Organon
Implanon Used for contraception.
Nexplanon Used for contraception.
Teva Branded Pharm
Quartette Used for contraception.
Seasonale Used for contraception in women.
Seasonique Used for preventing pregnancy in women using oral contraceptives.
Loseasonique Used for contraceptive purposes.
Loestrin 24 Fe

(uses Ethinyl Estradiol; Norethindrone Acetate)

Used for preventing pregnancy.
Wyeth Pharms Inc
Lybrel Used for contraception.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ethinyl Estradiol; Norethindrone Acetate. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Apil
Lo Loestrin Fe


Apart from brand drugs containing the same ingredient, some generics have also been filed for Ethinyl Estradiol; Norethindrone Acetate, Taytulla's active ingredient. Check the complete list of approved generic manufacturers for Taytulla





About Taytulla

Taytulla is a drug owned by Allergan Pharmaceuticals International Ltd. It is used for contraception. Taytulla uses Ethinyl Estradiol; Norethindrone Acetate as an active ingredient. Taytulla was launched by Apil in 2013.

Approval Date:

Taytulla was approved by FDA for market use on 19 April, 2013.

Active Ingredient:

Taytulla uses Ethinyl Estradiol; Norethindrone Acetate as the active ingredient. Check out other Drugs and Companies using Ethinyl Estradiol; Norethindrone Acetate ingredient

Treatment:

Taytulla is used for contraception.

Dosage:

Taytulla is available in capsule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.02MG;1MG CAPSULE Prescription ORAL